Oculis Holding AG (OCS) Other Non-Current Liabilities (2023 - 2026)
Oculis Holding AG (OCS) posted quarterly Other Non-Current Liabilities of $26.2 million for Q1 2026, up 57.89% year-over-year from $16.6 million in Q1 2025, and up 44.81% quarter-over-quarter from $18.1 million in Q4 2025.
Oculis Holding AG (OCS) Other Non-Current Liabilities (2023 - 2026) Analysis & Trends
Oculis Holding AG's Other Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $26.2 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 57.89% year-over-year to $26.2 million; the TTM figure through Mar 2026 stood at $26.2 million (up 57.89% YoY), while the FY2025 annual figure was $17.5 million, down 22.61% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $26.2 million, up from $18.1 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $26.2 million in Q1 2026, with the low at $4.8 million in Q2 2023.
- The 4-year median for Other Non-Current Liabilities is $12.4 million (2025), against an average of $13.5 million.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities surged 274.31% in 2024, then declined 20.06% in 2025.
- Oculis Holding AG's Other Non-Current Liabilities stood at $6.1 million in 2023, then soared by 274.31% to $22.7 million in 2024, then declined by 20.06% to $18.1 million in 2025, then jumped by 44.81% to $26.2 million in 2026.
- Business Quant data shows OCS's Other Non-Current Liabilities at $26.2 million in Q1 2026, $18.1 million in Q4 2025, and $15.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.23 Mn |
| Dec 31, 2025 | 18.11 Mn |
| Sep 30, 2025 | 15.18 Mn |
| Jun 30, 2025 | 18.25 Mn |
| Mar 31, 2025 | 16.61 Mn |
| Dec 31, 2024 | 22.66 Mn |
| Sep 30, 2024 | 9.01 Mn |
| Jun 30, 2024 | 8.14 Mn |
| Mar 31, 2024 | 9.67 Mn |
| Dec 31, 2023 | 6.05 Mn |
| Sep 30, 2023 | 7.45 Mn |
| Jun 30, 2023 | 4.78 Mn |